Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
Olivier Bouché, Department of Gastroenterology and Digestive Oncology, Hôpital Robert Debré, CHU Reims, Reims 51000, France
Meher Ben Abdelghani, Oncology Department, Centre Paul Strauss, Strasbourg 67000, France
Jean-Luc Labourey, Oncology Department, Centre Hospitalier, Carcassonne 11000, France
Simon Triby, Medical Department, AMGEN France, Boulogne-Billancourt 92100, France
René-Jean Bensadoun, Radiation Oncology, Centre de Haute Energie, Nice 06000, France
Thomas Jouary, Dermatology Department, Hôpital Saint-André, CHU de Bordeaux, Bordeaux 33000, France
Gaétan Des Guetz, Oncology Department, Avicenne Hospital, Bobigny 93000, France
Author contributions: Bouché O, Ben Abdelghani M, Labourey JL, Bensadoun RJ, Jouary T, and Des Guetz G participated to the design of the study; Bouché O, Ben Abdelghani M, Labourey JL, Bensadoun RJ, Jouary T, Des Guetz G, and Triby S participated to the collection and interpretation of data, and revised the manuscript.
Supported by Amgen 20090656 POPEC.
Institutional review board statement: Study protocol, information sheet and all other relevant documents received the approval of CCTIRS (French consultative committee for the processing of information in the field of health research).
Informed consent statement: The study was non-interventional and patients were informed both orally and in writing on the objectives of the study. The study was conducted according to the current revision of the 1964 Helsinki declaration and with the French laws and regulations.
Conflict-of-interest statement: Bouché O: Amgen, Roche, Merck Sereno, Bayer, Pierre Fabre, Servier; Ben Abdelghani M: Amgen, Sanofi, Bayer, Roche, Servier; Triby S: Amgen employee; Labourey JL, Bensadoun RJ, Jouary T, and Des Guetz G: no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the “STROBE Statement—checklist of items” and the manuscript was prepared and revised according to the “STROBE Statement-checklist of items”.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Olivier Bouché, MD, Professor, Department of Gastroenterology and Digestive Oncology, Hôpital Robert Debré, CHU Reims, Avenue du Général Koenig, Reims 51092, France. email@example.com
Telephone: +33-326-783113 Fax: +33-326-788836
Received: January 17, 2019
Peer-review started: January 18, 2019
First decision: January 30, 2019
Revised: February 7, 2019
Accepted: February 22, 2019
Article in press: February 23, 2019
Published online: August 7, 2019